Electrochemical Point-Of-Care Cerebrospinal Fluid Detection

Tech ID: 33898 / UC Case 2022-956-0

Brief Description

A revolutionary device for the diagnosis of cerebrospinal fluid (CSF) leaks with rapid, accurate, and low-volume sampling at the point of care.

Full Description

Researchers at UC Irvine developed a pioneering "lab-on-a-chip" point-of-care device leveraging electrochemical-aptamer based electrodes for the detection of cerebrospinal fluid (CSF). Utilizing custom-designed aptamers specific to beta-2 transferrin protein, this non-invasive device promises to deliver results within minutes, requiring only minimal sample volumes and ensuring accuracy even in samples contaminated with other bodily fluids.

Suggested uses

  • Hospitals and emergency departments for immediate CSF leak detection. 
  • Clinics and primary care settings for routine screening and diagnosis. 
  • Neurology and neurosurgery departments for pre- and post-operative evaluation. 
  • Research institutions for studying CSF dynamics and related diseases.

Advantages

  • Rapid detection of CSF within minute, enhancing patient care. 
  • High sensitivity and specificity for CSF-specific biomarkers, enabling accurate diagnosis. 
  • Low sample volume requirement, facilitating easier sample collection.
  • Non-invasive with potential for self-administration, improving patient comfort and compliance. 
  • Portable and easy to use, akin to a glucometer, for use in various healthcare settings. 
  • Reduces the need for costly, time-consuming laboratory tests and specialized imaging.

Patent Status

Country Type Number Dated Case
United States Of America Published Application 20240255462 08/01/2024 2022-956
 

Additional Patent Pending

State Of Development

Experimental stage (in vitro demonstrations using clinical samples).

Related Materials

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As


5270 California Avenue / Irvine,CA
92697-7700 / Tel: 949.824.2683
  • Facebook
  • Twitter
  • Twitter
  • Twitter
  • Twitter